Blueprint Medicines Corp (2L9.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 08:05AM CEST. Market open.
| Previous close | 100.00 |
| Open | 99.80 |
| Bid | 100.05 x 0 |
| Ask | 102.30 x 0 |
| Day's range | 99.80 - 99.80 |
| 52-week range | 41.00 - 101.95 |
| Volume | |
| Avg. volume | 173 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
- Zacks
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
- Insider Monkey
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript May 2, 2024 Blueprint Medicines Corporation misses on earnings expectations. Reported EPS is $ EPS, expectations were $-1.64. Blueprint Medicines Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. […]
© 2024 Yahoo. All rights reserved.